Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 9,377 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Onychomycosis
Interventions: DBI-001, DBI-002, Aqueous Gel; Biological
Lead sponsor: DermBiont, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Encino, California • New Brighton, Minnesota • Portland, Oregon + 2 more

Conditions: Ischemic Stroke
Interventions: SOLITAIRE™ Device, MERCI® Device; Device
Lead sponsor: Medtronic Neurovascular Clinical Affairs; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Portland, Oregon • Tacoma, Washington

Conditions: Infections, Papillomavirus
Interventions: Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 11 Years to 18 Years · Female only
Enrollment: 1,330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 36
States / cities: Fullerton, California • Long Beach, California • Sacramento, California + 31 more

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Autism Spectrum Disorder
Interventions: Opt-In Early Latinx intervention, Opt-In Early Rural Intervention; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Months and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Hartford, Connecticut • Portland, Oregon

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Inotuzumab Ozogamicin, Lumbar Puncture, Ponatinib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 283
States / cities: Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 175 more

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 65
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more

Conditions: Reproductive Health
Interventions: Families Matter 2, Living as a Safer Teen; Behavioral
Lead sponsor: Portland State University; Other
Eligibility: 13 Years to 80 Years
Enrollment: 945 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumors
Interventions: GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more

Conditions: Posttraumatic Stress Disorder, Depression
Interventions: Internet Mindfulness Meditation, Individual Mindfulness Meditation; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions: Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year to 49 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 20 more

Conditions: Malignant Mesothelioma
Interventions: everolimus; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 129
States / cities: Tucson, Arizona • Los Angeles, California • Marysville, California + 94 more

Conditions: Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions: Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 507
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 28
States / cities: Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases, Hereditary Spastic Paraparesis
Interventions: No intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 80 Years
Enrollment: 475 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 29
States / cities: Phoenix, Arizona • Orange, California • Jacksonville, Florida + 24 more

Conditions: Erythemato-telangiectatic Rosacea
Interventions: BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more

Conditions: Fertility Issues, Single-Gene Defects
Interventions: Embryo genome sequencing, Parents genome sequencing; Other
Lead sponsor: GenEmbryomics Pty. Ltd; Industry
Eligibility: 18 Years to 48 Years
Enrollment: 100 participants
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Kirkland, Washington

Conditions: Infrarenal Abdominal Aortic Aneurysm
Interventions: Anaconda Stent Graft System, Anaconda ONE-LOK Stent Graft System; Device
Lead sponsor: Terumo CVS; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 18
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 14 more

Conditions: Sleep Problems
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Years to 9 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Houston, Texas

Conditions: Acromegaly
Interventions: GHR-LRX; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Boston, Massachusetts • Las Vegas, Nevada + 4 more

Conditions: COVID-19
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more

Conditions: Hematologic Neoplasms
Interventions: BMS-986016, BMS-936558; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Plaque Psoriasis
Interventions: Placebo, ABT-874; Drug · Biological
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 1,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 93
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more

Search by objective public record fields.

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

Opt-In Early Pilot Study

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Improving the Reproductive Health of Families

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Mindfulness Meditation Format Pilot Study

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

Whole Genome Sequencing (WGS) on IVF Embryos and Individual Patients

The Vascutek AnacondaTM Stent Graft System Phase II IDE Study

Understanding Sleep Problems in Children With Autism Spectrum Disorder

A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

A Study of Baricitinib (LY3009104) in Participants With COVID-19

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis